Post-transplant diabetes mellitus — Risk factors and effects on the function and morphology of the allograft by Borda, Bernadett et al.
0231–424X/$ 20.00 © 2012 Akadémiai Kiadó, Budapest
Acta Physiologica Hungarica, Volume 99 (2), pp. 206–215 (2012)
DOI: 10.1556/APhysiol.99.2012.2.14
Post-transplant diabetes mellitus – Risk factors and 
effects on the function and morphology of the allograft
B Borda1,  Cs Lengyel2, E Szederkényi1, J Eller3, Cs Keresztes4, G Lázár1
1Department of Surgery, Faculty of Medicine, University of Szeged, Szeged, Hungary,
2First Department of Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary,
3Department of Medical Informatics, Faculty of Medicine, University of Szeged, Szeged, Hungary
4Department of Medical Communication and Translation, University of Szeged, Szeged, Hungary
Received: March 23, 2011
Accepted after revision: July 27, 2011
The incidence of post-transplant diabetes mellitus and its effects on the kidney allograft function and morphology 
were assessed. Patients were divided into three groups according to their glucose metabolism. Risk factors for 
diabetes were fi rst assessed, and then changes in renal function were checked. Morphological changes in the 
allografts were examined by protocol biopsies. The overall incidence of diabetes was 16%. The development of 
diabetes was infl uenced signifi cantly by the body mass index, the body weight and the age of the recipient. The 
incidence of diabetes was 8.6% in patients on cyclosporine A therapy and 28.8% in those on tacrolimus ( p < 0.05). 
As to the morphology of the kidney, a signifi cantly higher proportion of the biopsies showed severe interstitial 
fi brosis/tubular atrophy ( p = 0.0004) and subclinical acute rejection ( p = 0.001) in the diabetic group compared to 
the normal one. This clinical study has revealed that the adverse effect of diabetes on the allograft can be detected 
with protocol biopsy before the manifestation of a functional deterioration. 
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After kidney transplantation, almost 40% of overall mortality can be attributed to 
cardiovascular diseases. Diabetes mellitus following transplantation (Tx) is called post-
transplant diabetes mellitus (PTDM). According to the criteria of the American Diabetes 
Association (ADA), diabetes is present if the fasting blood glucose level is ≥ 7 mmol/L, or if 
the blood glucose level measured 2-h following the oral administration of 75 g glucose (Oral 
glucose tolerance test, OGTT) is ≥ 11.1 mmol/L. Impaired fasting glucose (IFG) is defi ned as 
a fasting blood glucose level of between 5.6 mmol/L and 6.9 mmol/L, whereas the normal 
value (N) for fasting blood glucose is < 5.6 mmol/L or impaired glucose tolerance (IGT) (2-h 
values in the OGTT) between 7.8 mmol/L and 11.0 mmol/L. PTDM is often not diagnosed, 
and diabetes without timely treatment is a high risk factor for cardiovascular diseases, graft 
function deterioration and death (3, 5, 6, 9, 13). PTDM and diabetes diagnosed before 
transplantation are equivalent risk factors for cardiovascular diseases. The ethiopathogenesis 
of PTDM is complex.  Endogenous factors, such as the body mass index (BMI), a positive 
family history, older age, hepatitis C and immunosuppressive (IS) therapy can all play a role 
in its development (15). The use of IS drugs, such as steroids (S), cyclosporine A (CsA) or 
tacrolimus (Tac), is a risk factor for the development of PTDM with an incidence ranging 
from 2 to 53% among renal transplant recipients (10,3). PTDM is caused by insuffi cient 
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insulin release in response to an increase in insulin resistance. Since calcineurin inhibitors 
(CNI) are commonly used with steroid, it is diffi cult to identify whether diabetes in post-
transplant setting is due to steroid, CNI or both (10). Long-term allograft failure because of 
interstitial fi brosis/tubular atrophy (IF/TA) with defi ned or undefi ned cause (11) is one of the 
most important reasons for kidney graft loss together with premature patient death with a 
functioning graft. However, the impact of post-transplant diabetes, or other glucose 
metabolism abnormalities developing after transplantation, on the progression of 
histopathological changes attributable to IF/TA in serial protocol biopsies during the fi rst 
year after transplantation have not been described in detail.
The aim of our study was to assess the incidence of diabetes in kidney transplant patients. 
Diabetes is known to damage the graft; however, it is uncertain whether this damage is 
manifested fi rst in a decreased renal function or in a morphological change. 
Patients and Methods
Between January 1, 2004, and December 31, 2008, 243 kidney transplantations were 
performed at the Department of Surgery, University of Szeged, Hungary. We enrolled patients 
who were alive, receiving treatment and were above the age of 18 years in 2009, and who had 
received a primary cadaver kidney transplant. Subjects who were under 18 years of age, had 
a live donor transplant, had known diabetes mellitus prior to transplantation, had already died 
by the year 2009 or underwent graftectomy were excluded from the study. Thus, 154 patients 
were included in the study. 
Fasting blood glucose level of patients was measured one year after the transplantation. 
Based on ADA criteria, patients were divided into the following groups: PTDM, IFG, IGT 
and N. OGTT was performed in each patient. Patients with blood glucose level ≥ 11 mmol/L 
were selected into the PTDM group. Each patient had ≥ 11 mmol/L 2-hour postload blood 
glucose level in this group. Patients with normal glucose metabolism formed the control 
group. In 2008, the measurement of glycated hemoglobin (HbA1C) was introduced.  In 
diabetes mellitus, the measurement of HbA1C serves for the 2–3-month retrospective 
monitoring of carbohydrate metabolism. 
Of the immunosuppressants employed, we studied the effects of the CNI, CsA and Tac 
on the glucose metabolism. We also examined whether steroids, besides calcineurin inhibitors, 
have an infl uence on the development of PTDM. 
A total of 137 patients received CNI-based immunosuppression. Seventy patients were 
taking CsA and 22 of them also received a steroid. Tac was given to 67 patients, and 19 of 
them were taking a steroid as well. Seventeen patients were treated with CNI-free 
immunosuppressive therapy (Table I). 
Table I. Immunosuppressive therapy 1 year after transplantation
+ MMF – MMF Total
+S –S SRL/EVR +S –
CsA 19 23 25 3 70
Tac 17 24 24 2 67
SRL/EVR 10 5 – 2 17
Total 46 52 49 7 154
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Mechanism of action of the calcineurin inhibitors
Calcineurin inhibitors (CsA and Tac) differ from their predecessor immunosuppressive drugs 
by virtue of their selective inhibition of the immune response. Their immunosuppressive 
effect depends on the formation of a complex with their cytoplasmic receptor proteins, 
cyclophilin for cyclosporine A and tacrolimus binding protein (FKBP) for tacrolimus. This 
complex binds with calcineurin, the normal function of which is to act as a phosphatase that 
dephosphorylates certain nuclear regulatory proteins and hence facilitates their passage 
through the nuclear membrane. Inhibition of calcineurin thereby impairs the expression of 
several critical cytokine genes that promote T-cell activation including those for IL-2, IL-4, 
interferon–γ, and tumor necrosis factor-α. The transcription of other genes, such as CD40 
ligand and the proto-oncogenes is also impaired. 
Mechanism of action of the steroid
Steroid exerts two principal effects on the recipient immune system. First, within 4 to 8 hours 
of administration, they alter the circulation of lymphocytes causing them to be sequestered in 
the reticuloendothelial system. Second, steroids inhibit the function of lymphocytes by 
interfering with soluble signals that are important for the recruitment of several types of 
immune cells to the rejection process (i.e. lymphokines and cytokines) (20). 
Functional and morphological examination of the allograft
Changes in renal function were assessed by the serum creatinine level and the estimated 
glomerular fi ltration rate (eGFR) in the different glucose metabolism groups. eGFR was 
calculated using the Cockroft-Gault (CG) and the Modifi cation of diet in renal disease 
(MDRD) formulas. 
Before the transplantation, a histological sample was taken from each kidney not yet 
implanted (“zero hour” biopsy). We studied the one-year protocol biopsies of those patients 
who had a normal histology result of the zero biopsy. The histology specimens of 115 
patients were evaluated. Seven patients disagreed to have biopsy and 32 patients were 
excluded from the study as the histological result of their zero-hour biopsy showed 
hypertensive renal disease. 
These biopsies were performed under ultrasound guidance with the prior consent of the 
patients. 16-G Tru-Cut needles and a biopsy gun were used to obtain tissue cylinders. 
Morphological examinations included standard light microscopic stainings hematoxylin–
eosin  PAS, trichrome and methenamine silver), and immunofl uorescence analysis of the 
frozen sections with antibodies to HLA class II antigens, complement 4d (C4d), C3, IgG, IgA 
and IgM.  Embedding for electron microscopy was carried out in all cases, and ultrastructural 
evaluation was performed optionally.  Renal lesions were graded and diagnosed according to 
the 2003 modifi cation of the Banff ’97 classifi cation. The histological changes were acute 
rejection (AR), calcineurin inhibitor toxicity (CNI-tox), IF/TA (21) – where IF/TA involved 
patients with grades II and III, whereas grade I was considered normal – pyelonephritis and 
others (acute tubular necrosis, glomerulonephritis, and BK polyomavirus nephritis). 
Our study was approved by the Regional Human Biomedical Research Ethics Committee 
of the Albert Szent-Györgyi Clinical Center, University of Szeged (Reg. No.: 17/2009). Each 
patient was provided with comprehensive information regarding the study. 
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Immunosuppression
Immunosuppressive drugs administered 1 year after transplantation
Tac is a macrolid molecule that has strong lipophilicity. The initial daily dose of Tac was 0.20 
mg/kg in two portions, and then the target blood trough level was 10–15 ng/mL for 6 weeks, 
and 5–10 ng/mL after week 6. CsA is a lipophilic, hydrophobic, cyclic peptide composed of 
11 amino acids.The initial dose of CsA was 8–10 mg/kg daily, in two portions, and then the 
target blood level was 1,300–1,600 ng/mL in month 1,900–1,300 ng/mL in months 2 and 3, 
750–950 ng/mL in months 4 to 6, and 700 ng/mL afterwards (blood levels were determined 
two hours after administration). Sirolimus (SRL) is a macrolid molecule with a structure 
similar to that of tacrolimus. The initial dose of sirolimus was 0.1 mg/kg once daily; the target 
blood trough level was 10–15 ng/mL for 6 weeks and then 5–10 ng/mL. In the case of 
everolimus (EVR), the initial dose was 0.02 mg/kg twice daily, and then the target trough 
level was 3–8 ng/mL. A 500 mg steroid was administered intravenously on day 0 in the 
operating room, immediately before restoring blood fl ow to the graft; 125 mg was administered 
intravenously on day 1, 32 mg orally on day 2, 24 mg orally on day 3, 16 mg orally on days 
4 to 28, 12 mg orally during month 2, 8 mg orally during month 3, and 4 mg orally during 
months 4 to 6. The dose was further decreased in problem-free cases. The daily dose of 
mycophenolate mofetil (MMF) was 2 g in two portions and was reduced by 50 or 75% in the 
event of gastrointestinal symptoms or leucopenia. Antithymocyte globulin (ATG) was 
administered 1.25 mg/kg for 7 to 21 days. Basiliximab was given on day zero within 2 hours 
prior to the operation 20 mg i.v. and 20 mg i.v. on day 4. 
 For the treatment of AR, steroid in a daily dose of 500 mg was administered intravenously 
for 3 days, followed by 250 mg per day, intravenously for 2 days. 
Statistical analysis 
For the comparison of mean values, t-test and one-way analysis of variance were used, as 
well as the Mann–Whitney and Kruskal–Wallis tests in cases of non-normality. The normal 
distribution of samples was tested by using the Kolmogorov–Smirnov test. Categorical data 
were analyzed by using chi-square and Fisher’s exact test. Temporal changes in renal function 
parameters were compared by using repeated measures ANOVA. The multivariable 
dependence of PTDM on both categorical and continuous data was analyzed by means of 
logistic regression with stepwise (forward) model selection based on the likelihood ratio 
criterion. SPSS version 15.0 (© 2007 SPSS Inc.) was used for statistical analysis.
 
Results
 After OGTT, 115 patients (75%) were assigned to the control group (having normal glucose 
metabolism), 8 patients (5%) to the IFG group, 6 patients (4%), to the IGT group and 25 
patients (16%) to the PTDM group. Ten of the diabetic patients were receiving treatment: 3 
of them were on insulin, whereas 7 were taking oral antidiabetics. Fifteen patients were not 
given treatment as their abnormal glucose metabolism was identifi ed during the examination. 
The level of HbA1C was 4.2 ± 0.2% in the N group, 4.9 ± 0.5% in IFG group, 5.2 ± 0.9% in 
patients with IGT and 10.4 ± 3.6% in the PTDM group. The difference between the HbA1C 
levels was signifi cant ( p < 0.001) when comparing the N and the PTDM groups. Of the initial 
and post-transplantation data relating to the donor and the recipient, BMI ( p = 0.003), body 
weight ( p = 0.02) and age of the recipient ( p = 0.005) differed signifi cantly in the control and 
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the PTDM groups (Table II). As regards the immunosuppressive therapy, the ratio of patients 
who developed PTDM was 8.6% in those taking CsA, and 26.8% in those on Tac; the 
difference was signifi cant ( p = 0,004; Table III). In the case of combined CsA–S treatment, 
10.4% of the patients developed diabetes, and there was a signifi cant difference if we 
compared this to the group of patients taking CsA without steroids 4.5% ( p = 0.044). The 
incidence of newly developed diabetes among patients on the Tac–S combination was 27.7%; 
compared to the incidence rate in patients receiving steroid-free immunosuppression 21.1%, 
which was not signifi cantly different ( p = 0.846). No signifi cant difference, in regard to 
the development of diabetes, was found between the normal and the PTDM groups in case of 
the combinations of MMF and Tac ( p = 0.76), SRL and Tac ( p = 0.53), and EVR and Tac 
( p = 0.43). 
Table II. Donor and recipient data  
N (n = 115)
Mean ± SD
IFG (n = 8)
Mean ± SD
IGT (n = 6)
Mean ± SD
PTDM (n = 25)
 Mean ± SD
p value
Donor data
Gender (female/male) 49/66 3/5 1/5 8/17
Age (years) 43.63 ± 12.31 47.2 ± 9.7 45.5 ± 5.4 45.52 ± 8.54 0.529
Urine production in the 
last 24 h (ml)
5,847 ± 3,096 4,820 ± 1,814 4,956 ± 1.574 6,033 ± 3,488 0.454
Creatinine (μmol/L) 91.69 ± 38.98 97.98 ± 44.5 94.46 ± 38.67 95.96 ± 42.91 0.593
Transplant factors
CIT (h) 16 ± 4 17 ± 3 15 ± 4 15 ± 2 0.104
HLA mismatches 3.4 ± 1.44 3.4 ± 1.38 3.1 ± 1.51 3.2 ± 1.24 0.458
Initial recipient data
Gender (female/male) 43/72 4/4 2/4 9/16
Age (years) 41.82 ± 4.71 49.02 ± 6.78 48.03 ± 3.47 58.58 ± 5.86 0.005*1
Body weight (kg) 71.42 ± 14.22 72.31 ± 12.87 72.67 ± 11.89 74.14 ± 21.17 0.258
Body height (cm) 168.53 ± 10.61 167.36 ± 11.09 171.56 ± 8.79 170.60 ± 11.67 0.427
BMI (kg/m2) 25 ± 1.2 26 ± 2.4 26 ± 3.2 27 ± 1.3 0.357
Recipient data 1 year after Tx
Body weight (kg) 74.42 ± 14.22 77. 31 ± 12.87 80 ± 10.45 89.14 ± 21.17 0.02*2
Body height (cm) 168.53 ± 10.61 167.36 ± 11.09 171.56 ± 8.79 170.60 ± 11.67 0.27
HbA1C (%) 4.2 ± 0.2 4.9 ± 0. 5 5.2 ± 0.9 10.4 ± 3.6 < 0.001
*3
BMI (kg/m2) 25 ± 2.8 26 ± 3.8 25 ± 4.2 30 ± 3.5 0.003*4
*1 p = 0.005; *2 p = 0.02; *3 p = 0.001; *4 p = 0.003 indicating signifi cant difference between normal and post-
transplant diabetes groups.
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Table III.  Incidence of diabetes mellitus and impaired glucose tolerance among patients treated with 
cyclosporine A or tacrolimus
 N IFG IGT PTDM Total
CsA 59 (84.3%) 3 (4.2%) 2 (2.8%) 6 (8.6%)*1 70
Tac 43 (64.0%) 2 (2.9%) 4 (5.9%) 18 (26.8%)*2 67
p value 0.25 0.31 0.53 0.004
*1,*2 p < 0.05 indicating signifi cant differences between the cyclosporine A and tacrolius groups. 
Function and morphological changes of the allograft
Studying the functional changes of the allograft one year after the transplantation, we found 
that the serum creatinine value was 151.56 ± 44.38 μmol/L in normal patients and 158.80 ± 
49.74 μmol/L in the PTDM group. There was no signifi cant difference between the normal 
and the PTDM groups (p = 0.54). The eGFR (calculated by using the CG formula) in the N, 
and PTDM groups was 57.97 ± 20.25 and 52.95 ± 17.89 mL/min/1.73 m2, respectively. We 
had similar results when calculating eGFR using the MDRD formula. The calculated eGFR 
in the N and PTDM groups was 52.28 ± 18.99 and 49.54 ± 18.04 mL/min/1.73 m2, respectively. 
No signifi cant difference was found between the N and the PTDM groups when comparing 
the eGFR values (p = 0.34 with the CG and p = 0.46 with the MDRD formula). The post-Tx 
serum creatinine and eGFR levels in the groups with a different glucose metabolism status 
were compared by using the repeated measures ANOVA statistical analysis. Regarding the 
morphological changes of the kidney, there was a signifi cant difference between the PTDM 
and the N groups in the frequency of severe IF/TA ( p = 0.0004) and subclinical acute rejection 
( p = 0.001), whereas no signifi cant difference could be demonstrated in morphological signs 
of CNI toxicity ( p = 0.075) between the two groups (Table IV, Fig. 1). According to the 
results of a stepwise logistic regression analysis of the data on recipients (gender, age, serum 
creatinine, urine production in the last 24 hours) and donors (age, gender, serum creatinine, 
eGFR, BMI, body weight and IS), calcineurin inhibitors had the major effect on the 
morphological changes of the kidneys. Diabetes mellitus markedly increased the risk of 
AR and IF/TA (AR: p = 0.025, OR = 7.2, CI = 1.276–40.960; IF/TA: p = 0.0004, OR = 24.9, 
CI = 4.5–138.219).  
Table IV. Protocol biopsy results in the different glucose metabolism groups
AR CNI-tox IF/TA Pyelonephritis Other Normal
N (n = 77) 13 (16.8%) 9 (11.6%) 10(12.9%) 2(2.6%) 1(1.3%) 42(54.5%)
IFG (n = 8) 1 (12.5%) 1 (12.5%) 2 (25%) 0 (0%) 2(25%) 2 (25%)
IGT (n = 5) 1 (20%) 0 (0%) 2 (40%) 0 (0%) 1(20%) 1 (20%)
PTDM (n = 25) 6 (24%) 3 (12%) 13 (52%) 1(4%) 0 (0%) 2 (8%)
p value 
(compared N and PTDM)
0.001 0.075 0.0004 0.453 0.287 0.003
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Fig. 1. Results of the one-year protocol biopsies in the 4 patient groups
Discussion
The incidence of PTDM was 16% in our patient population. In the studies by Valderhang et 
al. (28) the incidence of diabetes has been 17% and 14%, respectively.  Kamar et al. (12) and 
Schiel et al. (22) have found similar results, namely that the risk factors of PTDM include not 
only the immunosuppressive agents, but also family history and age, body weight and BMI 
of the recipient, and these are at least as important in the development of diabetes (18, 19, 24, 
29, 30). Our clinical study revealed that both IS agents and age, and body weight and BMI of 
the recipient infl uenced the development of diabetes. In regard to immunosuppressive 
therapy, we found a signifi cant difference between the effects of Tac and CsA on glucose 
metabolism (26.8% vs. 8.6%) (29, 30, 31). In a study by Vincenti et al., the incidence of 
diabetes has been 33.6% with Tac and 26% with CsA treatment (31), whereas Heisel et al. 
report that the incidence of PTDM has been 16.5% in case of Tac and 9.8% in case of CsA 
(10). The difference is signifi cant in both studies. We found a signifi cant difference between 
combined CsA–S treatment and S-free CsA treatment in regard to the development of 
diabetes, whereas the difference was not signifi cant between combined Tac–S treatment and 
S-free Tac treatment (9). Greater steroid exposure was associated with the development of 
glucose metabolism abnormalities in the CsA-group but not among tacrolimus-treated 
patients. This suggests that steroid played a major role in the development of diabetes 
occurring in the CsA-treated patients. Steroids are diabetogenic and cause insulin resistance. 
The long-term use of steroids in organ transplant recipients can lead to post-transplantation 
diabetes, so reduced steroids and steroid-free drug regimens have been instituted at many 
transplant centers. Calcineurin inhibitors have also been associated with post-transplantation 
diabetes. Steroids produce increased insulin resistance, whereas calcineurin inhibitors 
primarily decrease insulin secretion. Cyclosporine A appears to be less diabetogenic than 
tacrolimus, but both agents may have a direct impact on the transcriptional regulation of 
insulin gene expression in the pancreatic β cells. The exact mechanism of calcineurin inhibitor 
induced toxicity to β cell is unknown. The diabetogenic effect of tacrolimus may be reversible, 
as evidenced by observations that impaired insulin secretion was reversed 3 days after 
tacrolimus discontinuation and that insulin secretion improved after the reduction of 
tacrolimus through blood concentration. With the above understanding, in the following 
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sections, genes related to diabetes or to the mechanism of developing diabetes are compared 
with the genes associated with calcineurin inhibitor induced diabetes (7). When examining 
the different immunosuppressive combinations, we did not fi nd MMF and SRL to have a 
diabetogenic effect (3). One year after transplantation, no signifi cant difference could be 
shown between diabetic patients and normal patients in regard to their serum creatinine and 
GFR levels (9). Regarding the morphology of the kidneys, we observed different results in 
the one-year protocol biopsies. There were signifi cantly more frequent interstitial fi brosis/ 
tubular atrophy and acute rejection in the diabetic group than in the normal group, whereas 
the two groups did not differ in regard to CNI-tox (4, 11, 17, 21, 22). In the study by Arif et 
al., diabetic and normal patients have differed signifi cantly in IF/TA ( p < 0.001) (2). This 
confi rms that the disruption of the glucose homeostasis severely damages the allograft, which 
is fi rst manifested in the morphology, followed by a decrease in renal function. One year after 
kidney transplantation diabetic nephropathy (especially mesangial matrix increase and 
arteriola hyalinosis) does not develop, however, permanent hyperglycemia may result in 
morphological changes of the allograft. In IF/TA, hyperglycemia may lead to fi brogenesis by 
decreasing the number of functioning nephrons. One year after normal “zero-hour” biopsy 
diabetes may damage the allograft, however, no deterioration in function can be detected. 
Histological changes can be identifi ed by protocol biopsy in time, and accordingly diabetic 
nephropathy and end stage renal failure can be prevented. One year after transplantation, 
differences in the functional and morphological state of the allograft were presumed to be due 
to the phenomenon that the kidney tries to compensate for the loss of functioning kidney 
tissues with the overburdening, hypertrophy and hyperfi ltration of the intact glomeruli. 
Therefore, the allograft shows morphological changes but no functional ones. The 
cardiovascular risk of kidney transplant patients may be decreased, and the long-term survival 
of the graft may be increased by the timely recognition and treatment of diabetes (1, 3). It is 
important to check glucose metabolism regularly by measuring the fasting blood glucose 
level and the level of HbA1C every three months. Later, in case of a worsening glucose 
metabolism, a reduction in the dose of the calcineurin inhibitor and even a switch to a 
calcineurin inhibitor-free combination may be considered. Thus, with the timely initiation of 
treatment, the graft may be preserved in the long term, and the risks of diabetes may be 
decreased. By means of the protocol biopsy, an individually tailored immunosuppressive 
therapy can be set up for each patient, which may not only promote allograft function, but 
might also increase the survival of the patient. 
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